News

The US Food and Drug Administration is starting to publish letters the agency sent to pharmaceutical companies when their ...
The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...
The U.S. Food and Drug Administration on Thursday published more than 200 of its so-called complete response letters to ...
The U.S. Food and Drug Administration on Thursday publicly shared over 200 archived so-called complete response letters related to medicines that were later approved, in a bid to improve transparency ...
The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.
The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving ...
When the FDA unexpectedly uploaded around 200 drug rejection letters this week, the regulator provided a rare glimpse in | ...
After 100 days as FDA Commissioner, Dr. Marty Makary lays out his vision for reform, starting with the broken systems he's ...
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
FDA Proposal to Publish Drug-Rejection Letters Is Good for Pharma, Even if Pharma Doesn't Agree. By Trista Morrison. Updated on: May 26, 2010 / 11:35 AM EDT / MoneyWatch ...
Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.
In its complete response letter, the FDA cited insufficient evidence establish deramiocel's effectiveness for cardiomyopathy ...